The U.S Food and Drug Administration has approved Nucala, British drugmaker GSK's asthma drug, to treat some patients with a ...

GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval ...

Recently, Regeneron ( REGN -1.41%) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its ...

GSK stock dips 0.6% after six-session gain streak. EU panel backs Blenrep for multiple myeloma, while FDA expands asthma ...

Shares of Merus NV (NASDAQ:MRUS) were trading at $54.35, up $12.75, or 30%, on interim data as of Feb. 27 from the phase II trial of bispecific antibody petosemtamab in combination with Merck & Co.

Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...

CHMP gives positive opinions for new drugs from GSK, Roche & SpringWorks, including GSK's Blenrep, Roche's Itovebi & ...

Who doesn’t love a comeback story? Certainly not GSK, which has found a way to resuscitate its cancer treatment Blenrep as a ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.

The FDA has approved Nucala (mepolizumab) as an add-on maintenance treatment for certain COPD patients whose disease isn't ...

The FDA has granted approval to GSK's Nucala as an add-on maintenance treatment for adult patients suffering from inadequately controlled COPD.